← Back to headlines
Leerink Raises Merck & Co. Price Target on Cancer Drug Upside
Leerink has increased its price target for Merck & Co. Inc. (MRK), citing potential upside from the company's cancer drug portfolio.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
